Amgen Inc. $AMGN Shares Bought by MCF Advisors LLC

MCF Advisors LLC boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 48.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,468 shares of the medical research company’s stock after acquiring an additional 3,424 shares during the period. MCF Advisors LLC’s holdings in Amgen were worth $3,426,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Closed End Fund Advisors Inc. acquired a new position in Amgen during the fourth quarter worth about $262,000. First Command Advisory Services Inc. raised its position in Amgen by 5.8% during the fourth quarter. First Command Advisory Services Inc. now owns 2,151 shares of the medical research company’s stock worth $704,000 after acquiring an additional 118 shares during the last quarter. Patron Partners LLC raised its position in Amgen by 1.3% during the fourth quarter. Patron Partners LLC now owns 9,253 shares of the medical research company’s stock worth $3,029,000 after acquiring an additional 123 shares during the last quarter. OneAscent Financial Services LLC raised its position in Amgen by 11.6% during the fourth quarter. OneAscent Financial Services LLC now owns 2,777 shares of the medical research company’s stock worth $909,000 after acquiring an additional 288 shares during the last quarter. Finally, OneAscent Family Office LLC acquired a new position in Amgen during the fourth quarter worth about $205,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $349.58 on Friday. The company has a market cap of $188.67 billion, a PE ratio of 24.33, a price-to-earnings-growth ratio of 3.47 and a beta of 0.42. Amgen Inc. has a 12 month low of $267.83 and a 12 month high of $391.29. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The company has a 50-day simple moving average of $341.35 and a 200-day simple moving average of $345.47.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities analysts anticipate that Amgen Inc. will post 22.38 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on AMGN shares. UBS Group lifted their target price on shares of Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Leerink Partners restated a “market perform” rating and set a $355.00 target price on shares of Amgen in a research report on Thursday, March 5th. The Goldman Sachs Group set a $389.00 target price on shares of Amgen in a research report on Friday. Daiwa Securities Group cut their target price on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Finally, Wells Fargo & Company lifted their price target on shares of Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a report on Thursday, March 19th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $353.81.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.85% of the stock is currently owned by company insiders.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received European Commission marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for adults with extensive-stage small cell lung cancer, expanding a key oncology product into the European market and improving the drug’s commercial outlook. Article Title
• Positive Sentiment: Amgen also showed fresh momentum in autoimmune therapies, with new Phase 3 and real-world data on UPLIZNA and TAVNEOS presented at EULAR 2026, which supports the company’s growing presence in high-value specialty medicine niches. Article Title
• Positive Sentiment: One analyst note upgraded Amgen to a cautious Buy, citing improved fundamentals, a diversified pipeline, and growth drivers such as Imdelltra, Uplizna, Tepezza, and Repatha. Article Title

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.